Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression

OncoImmunology

Volumn 3, Issue 4, 2014, Pages

  Deng, Liufu ^a   Liang, Hua ^a   Burnette, Byron ^a   Weichselbaum, Ralph R ^a   Fu, Yang Xin ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Antibody therapy; Myeloid derived suppressor cell; Negative signal; PD L1; Radiation therapy; T cell activation; TNF

Indexed keywords

ANTINEOPLASTIC AGENT; PROGRAMMED CELL DEATH LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; COLON CANCER; DRUG POTENTIATION; HUMAN; MOLECULARLY TARGETED THERAPY; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PROTEIN EXPRESSION; SUPPRESSOR CELL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; TUMOR REGRESSION; UPREGULATION;

EID: 84902578811     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28499     Document Type: Article

References (10)

1. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011; 11:239-53; PMID:21430696; http://dx.doi. org/10.1038/nrc3007
2. Liauw SL, Connell PP, Weichselbaum RR. New paradigms and future challenges in radiation oncology:an update of biological targets and technology. Sci Transl Med 2013; 5: 173sr2; PMID:23427246; http://dx.doi.org/10.1126/scitranslmed.3005148
3. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009; 114:589-95; PMID:19349616; http://dx.doi.org/10.1182/blood-2009-02-206870
4. Liang H, Deng L, Chmura S, Burnette B, Liadis N, Darga T, Beckett MA, Lingen MW, Witt M, Weichselbaum RR, et al. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol 2013; 190:5874-81; PMID:23630355; http://dx.doi.org/10.4049/ jimmunol.1202612
5. Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012; 366:2517-9; PMID:22658126; http://dx.doi.org/10.1056/NEJMe1205943
6. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi. org/10.1038/nrc3239
7. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
8. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi. org/10.1056/NEJMoa1305133
9. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 2014; 124:687-95; PMID:24382348; http://dx.doi.org/10.1172/ JCI67313
10. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/ nri3175